Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial
| Autor: | Xiaomao Guo, Yong Liu, Guo-Liang Jiang, Liu Mina, Xue-hui Shi, Kuaile Zhao, Wei-qiang Yao |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Adult
Male Oncology lcsh:Medical physics. Medical radiology. Nuclear medicine medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment lcsh:R895-920 lcsh:RC254-282 Esophageal squamous cell carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols Carcinoma Humans Medicine Radiology Nuclear Medicine and imaging Prospective Studies Esophagus Prospective cohort study Survival rate Long-term follow-up Aged Chemotherapy business.industry Research Chemoradiotherapy Middle Aged Prognosis medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Survival Rate Clinical trial Radiation therapy medicine.anatomical_structure Chemoradiation Radiology Nuclear Medicine and imaging Lymphatic Metastasis Carcinoma Squamous Cell Quality of Life Female Dose Fractionation Radiation Fluorouracil Cisplatin Neoplasm Recurrence Local business Follow-Up Studies |
| Zdroj: | Radiation Oncology, Vol 7, Iss 1, p 142 (2012) Radiation Oncology (London, England) |
| ISSN: | 1748-717X |
| DOI: | 10.1186/1748-717x-7-142 |
| Popis: | Purpose To investigate the long-term outcome of esophageal squamous cell carcinoma (SCC) treated by irradiation with or without concurrent chemotherapy. Methods and materials A prospective clinical trial was carried out from 1998 to 2000. One hundred and eleven patients were randomly enrolled to receive either late course accelerated hyperfractionated irradiation (LCAF) or LCAF with concurrent chemotherapy (LCAF + CT). For LCAF, 41.4 Gy in 23 fractions was first delivered at five fractions per week, followed by 27 Gy in 18 fractions at two 1.5 Gy fractions a day. Concurrent chemotherapy of cis-platinum and 5-fluorouracil was administered for four cycles. Overall survival (OS), locoregional recurrence and distant metastasis were observed. Late toxicity was scored by RTOG criteria, and quality of life (QOL) was also evaluated. Results The median follow-up time was 24 months for all patients and 138 months for 17 living patients. Median survival time was 25 months and 32 months in LCAF and LCAF + CT (p = 0.653), respectively. For an entire group of patients, overall survivals were 34%, 27% and 22%; locoregional recurrence rates were 30%, 36% and 41%; and distant metastasis rates were 26%, 28% and 29% at 5-yr, 8-yr and 10-yr, respectively. Incidences of ≥ Grade 3 late toxicity were 29% at 10-yr. There were no statistically significant differences between LCAF and LCAF + CT with respect to the parameters mentioned above. Cumulative incidence of late toxicities of ≥ Grade 3 increased sharply after the attained age of 70 years. Eighty-eight percent of patients lived with good KPS (≥ 90) and 94% could eat regular or soft diet. Conclusion The long-term outcome of esophageal SCC patients who received LCAF or LCAF + CT was good. The locoregional and distant failures occurred more often in the first three years after treatment, but could continuously occur up to 10 years. The late toxicity was acceptable. Late toxicities ≥ Grade 3 were more likely to occur in elderly patients. QOL was good in living patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|